Institution address

Folkhälsan Inst of Genetics, Folkhälsan Research Center; Haartmaninkatu 8, Biomedicum 1; P.O. Box 63, FI-00014; Univ of Helsinki, Finland

Helsinki Univ Central Hospital, Dept of Medicine, Division of Nephrology; PL 263, FI-00029; Helsinki, Finland

Perra

Improving people's lives

Diabetes is the epidemic of our times with over 250 million patients diagnosed so far and rapidly growing numbers especially in the developing world. In Finland, the percentage of affected people is among the highest: an estimated tenth of the population have some form of diabetes. On the other hand, effective treatments exist for patients with diabetes, which ensures a good quality of life. So why do doctors and health care officials constantly warn about the impending calamity of diabetes?

It is true that in the short term the treatments cure the acute symptoms. However, the human body maintains a delicate balance of nutrients and other substances, and the current treatments in many cases cannot exactly mimic the natural regulation, even if the visible symptoms disappear. Broadly speaking, diabetes can be defined as the inability to consume glucose for energy. Medication or insulin injections are enough to keep the cells going, but more often than not the patients have an abnormally high amount of sugar in their blood.

We still do not know exactly what happens next, but the end result for some patients is dire: within the first decades of diabetes their kidneys start to fail, their eyesight progressively deteriorates and they will most likely die prematurely from a heart attack. Additional medication exists to slow down or even halt the disease process, but medical and life style intervention cannot be started early enough due to the lack of knowledge of the exact biological mechanisms.

The Finnish Diabetic Nephropathy Study was founded to uncover the risk factors and mechanisms of the diabetic complications. We specialize in type 1 diabetes, where the body depletes its own capacity to use glucose via a deranged immune reaction, typically at a young age. We wish to improve the care for these patients by increasing the knowledge of the genes and environmental factors involved, and thus reduce the human and societal cost until a cure for diabetes itself - if ever found - is available.

Per-Henrik Groop
Principal investigator
The FinnDiane Study Group

nephropathy = kidney disease

Latest from PubMed

In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010 Jul 28;

DDOST, PRKCSH and LGALS3, which encode AGE-receptors 1, 2 and 3, respectively, are not associated with diabetic nephropathy in type 1 diabetes. Diabetologia. 2010 May 21;

Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia. 2010 Apr 16;

Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes. J Intern Med. 2010 Mar;267(3):278-86

Age at onset and the risk of proliferative retinopathy in type 1 diabetes. Diabetes Care. 2010 Feb 25;

Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids. 2010 Jan 24;

Health-related quality of life in patients with type 1diabetes--association with diabetic complications (the FinnDiane Study). Nephrol Dial Transplant. 2009 Dec 27;

Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care. 2009 Sep;32(9):1689-93

Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule. Diabetologia. 2009 Nov 4;

Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia. 2009 Oct 10;

Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (The FinnDiane Study). Cardiovasc Diabetol. 2009 Oct 6;8(1):54

A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes. 2009 Aug 3;

Adult stature and diabetes complications in patients with type 1 diabetes: the FinnDiane Study and the diabetes control and complications trial. Diabetes. 2009 Aug;58(8):1914-20

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009 Jul;58(7):1651-8

Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy. Diabetes. 2009 Jul;58(7):1710-4

Early autonomic dysfunction in type 1 diabetes: a reversible disorder? Diabetologia. 2009 Jun;52(6):1164-72

Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2009 May;32(5):950-2

Effect of parental type 2 diabetes on offspring with type 1 diabetes. Diabetes Care. 2009 Jan;32(1):63-8

Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes. 2008 Sep;57(9):2480-7

Heritability of proliferative diabetic retinopathy. Diabetes. 2008 Aug;57(8):2176-80

View fewer items.

Updated 2009-08-06 by vpmakine.